Journal profile
Annals of Urologic Oncology
ISSN 2617-7765 · eISSN 2617-7773 · Asian Medical Press Ltd.(H.K.) · Hong Kong
Annals of Urologic Oncology: diamond open access (no APC); no APC; median 48 days to acceptance (21 articles, last 24 months); 23 articles in 2025.
Scope
Aims, scope and focus
Annals of Urologic Oncology is published by Asian Medical Press Ltd.(H.K.). By OpenAlex counts of its recent articles, its largest topics are Bladder and Urothelial Cancer Treatments, Prostate Cancer Treatment and Research and Renal cell carcinoma treatment, together about 38% of its articles. Its main subfields are Pulmonary and Respiratory Medicine and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Annals of Urologic Oncology (AUO, Ann Urol Oncol, p-ISSN: 2617-7765, e-ISSN: 2617-7773) publishes original research addressing the molecular, cellular and clinical aspects of urologic tumors. The journal’s scope encompasses studies on risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment strategies aimed at improving patient outcomes in urologic oncology. Each issue includes special topics, focusing primarily on three main subjects: bladder, prostate and kidney cancer. Additionally, the journal considers studies on adrenal tumor, testicular cancer, and penile carcinoma. AUO primarily publishes original research and review articles with high scientific and clinical relevance in physiopathology, diagnosis and treatment of urologic oncology.
From the journal's Aims & Scope
Editor-in-chief Sanjay GuptaPublisher website
Editorial board by country: 12 in mainland China (about 18%); most named United States 17, Mainland China 12, India 5, Türkiye 5, United Kingdom 4 (66 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Bladder and Urothelial Cancer TreatmentsMedicine14.3%
- Prostate Cancer Treatment and ResearchMedicine13.9%
- Renal cell carcinoma treatmentMedicine9.8%
- Prostate Cancer Diagnosis and TreatmentMedicine9.4%
- Urinary and Genital Oncology StudiesMedicine9.1%
- Urinary Bladder and Prostate ResearchMedicine5.9%
- Cancer Immunotherapy and BiomarkersMedicine3.5%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
DOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- h-index
- 4OpenAlex ·
- i10-index
- 0OpenAlex ·
- 2-year mean citedness
- 0.38OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 130 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 6 | 6 | 18 |
| 2025 | 23 | 23 | 23 |
| 2024 | 26 | 26 | 16 |
| 2023 | 22 | 22 | 12 |
| 2022 | 12 | 12 | 10 |
| 2021 | 12 | 12 | 2 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
48 daysMedian, submission to acceptance · P25–P75 18 days – 64 days
- Acceptance to online
- median 10 days (21 articles)
- Submission to online
- median 58 days
- Sample
- 21 articles with submission and acceptance dates (34 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 4 weeksLetPub ·
- Desk decision
- 7 daysPublisher website ·
- Submission to publication (journal-reported)
- about 4 weeksDOAJ ·
- Peer review
- Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY-NC-ND | |
| LetPub | No APC | No | — | |
| Publisher website | No APC | — | — |
Other charges and waivers (author guidelines)
- Other fees
- No other fees
- Page charges
- No page charges
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Keywords
- ≥ 3
- Manuscript length
- ≤ 12,000 words
- Reference style
- ACS
Article types accepted10, with length limits
- case reportsCase Reports - Case Reports highlight unique or unexpected urologic oncology cases, including rare diagnosis, treatment outcome, or clinical course.Length not stated
- clinical trialClinical Trial - Clinical trial articles should describe interventional studies related to urologic oncology, including pilot studies, safety and efficacy trial…Length not stated
- letteriously published articles in AUO. Brief letters or commentaries are welcomed with no more than 1000 words and two figures or tables. Brief contents summary for …main text ≤ 1,000 words
- letters or commentsLetters or Comments - Brief letters or Commentaries provide critical feedback on previously published articles in AUO.Length not stated
- mini reviewMini Review - Mini reviews provide focused summaries of a current area of investigation and its recent developments.Length not stated
- original researchOriginal Research - Original research articles focused on molecular, cellular and/or clinical perspectives of urologic tumors with significant scientific value …Length not stated
- perspectives/ opinionsPerspectives/ Opinions - Perspective articles present viewpoints on specific areas of investigation, covering current advances and future directionsLength not stated
- reviewgeneral interest in urologic oncology. Review manuscripts must be at least 4000 words (excluding references) with a minimum of 80 references. Revmain text ≤ 4,000 words
- reviewsReviews - Authors are encouraged to submit comprehensive reviews on broad topics of general interest in urologic oncology. Review manuscripts must be at least 4…Length not stated
- systematic reviewSystematic Review - Systematic Review articles should synthesize previous research using well-defined methods to identify, categorize, analyze and report aggreg…Length not stated
Policy excerpts from the journal's websiteConflicts of interest, Publication ethics, License & copyright, Open access, Plagiarism
- Conflicts of interest Disclosures
Competing interests must be disclosed. Model summary
Each author must disclose any financial relationships relevant to the subject of the manuscript, including equity ownership, profit-sharing agreements, royalties, patents, and grants. While authors are not required to report specific amounts, they must indicate “none” if no such relationships exist.
Source ↗Publisher website ·- Publication ethics
IRB/ethics committee approval required for human and animal studies. Model summary
All studies involving human participants and/or animal research must be approved by institutional review board or equivalent ethics committee(s). The name of the approving ethics board must be included in the manuscript.
Source ↗Publisher website ·- License & copyright
CC-BY-NC-ND license. Model summary
AUO articles are published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND).
Source ↗Publisher website ·- Open access Open Access
AUO is a platinum open access journal. All articles are immediately available online upon publication. This model permits any medium to use and distribute the content for non-commercial aims, provided that proper credit is given to both the authors and the journal.
Source ↗Publisher website ·- Plagiarism
Plagiarism checked per COPE guidelines; plagiarism leads to rejection or retraction. Model summary
All submitted manuscript are checked for originality following the COPE guidelines. Manuscript with plagiarism including any form of copying (text, images, data, and ideas) without a proper attribution will result in rejection during the peer-review process or retraction after publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Asian Medical Press Ltd.(H.K.)
- Country or region
- Hong Kong
- Language
- English
- ISSN
- 2617-7765
- Electronic ISSN
- 2617-7773
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Annals of Urologic Oncology
How long does peer review take at Annals of Urologic Oncology?
Based on the dates recorded on 21 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 48 days (interquartile range 18–64 days); authors report an average review time of about 4 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Annals of Urologic Oncology?
According to the journal's author guidelines: Keywords: ≥ 3; Manuscript length: ≤ 12,000 words; Reference style: ACS. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Annals of Urologic Oncology based?
Of the 66 board members whose country the journal's board page names, 12 (about 18%) are in mainland China; the countries named most often are United States (17), Mainland China (12) and India (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Annals of Urologic Oncology?
According to LetPub and DOAJ records, Annals of Urologic Oncology is indexed in DOAJ.
Is Annals of Urologic Oncology open access, and what is the APC?
Annals of Urologic Oncology is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .